全文获取类型
收费全文 | 31861篇 |
免费 | 2718篇 |
国内免费 | 3728篇 |
出版年
2024年 | 107篇 |
2023年 | 680篇 |
2022年 | 816篇 |
2021年 | 1001篇 |
2020年 | 1091篇 |
2019年 | 1447篇 |
2018年 | 1129篇 |
2017年 | 1184篇 |
2016年 | 1244篇 |
2015年 | 1328篇 |
2014年 | 1689篇 |
2013年 | 2270篇 |
2012年 | 1314篇 |
2011年 | 1544篇 |
2010年 | 1265篇 |
2009年 | 1652篇 |
2008年 | 1724篇 |
2007年 | 1710篇 |
2006年 | 1596篇 |
2005年 | 1474篇 |
2004年 | 1310篇 |
2003年 | 1167篇 |
2002年 | 1052篇 |
2001年 | 837篇 |
2000年 | 712篇 |
1999年 | 760篇 |
1998年 | 598篇 |
1997年 | 554篇 |
1996年 | 508篇 |
1995年 | 516篇 |
1994年 | 490篇 |
1993年 | 380篇 |
1992年 | 349篇 |
1991年 | 346篇 |
1990年 | 270篇 |
1989年 | 252篇 |
1988年 | 229篇 |
1987年 | 213篇 |
1986年 | 170篇 |
1985年 | 198篇 |
1984年 | 203篇 |
1983年 | 142篇 |
1982年 | 170篇 |
1981年 | 118篇 |
1980年 | 120篇 |
1979年 | 104篇 |
1978年 | 81篇 |
1977年 | 46篇 |
1976年 | 43篇 |
1974年 | 25篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
921.
Nataly Kravchenko‐Balasha 《Proteomics》2020,20(13)
Cancer research is striving toward new frontiers of assigning the correct personalized drug(s) to a given patient. However, extensive tumor heterogeneity poses a major obstacle. Tumors of the same type often respond differently to therapy, due to patient‐specific molecular aberrations and/or untargeted tumor subpopulations. It is frequently not possible to determine a priori which patients will respond to a certain therapy or how an efficient patient‐specific combined therapy should be designed. Large‐scale datasets have been growing at an accelerated pace and various technologies and analytical tools for single cell and bulk level analyses are being developed to extract significant individualized signals from such heterogeneous data. However, personalized therapies that dramatically alter the course of the disease remain scarce, and most tumors still respond poorly to medical care. In this review, the basic concepts of bulk and single cell approaches are discussed, as well as their emerging role in individualized designs of drug therapies, including the advantages and limitations of their applications in personalized medicine. 相似文献
922.
Meimei Liu Meihua Jin Linmei Li Yahui Ji Fengjiao Zhu Yong Luo Tingjiao Liu Bingcheng Lin Yao Lu 《Proteomics》2020,20(13)
Multiplexed single‐cell protein secretion analysis provides an in‐depth understanding of cellular heterogeneity in intercellular communications mediated by secreted proteins in both fundamental and clinical research. However, it has been challenging to increase the proteomic parameters co‐profiled from every single cell in a facile way. Herein, a simple method to improve the multiplexed proteomic parameters of PDMS microwell based single‐cell secretion analysis platform by sandwiching PDMS stencil in between two antibody‐coated glass slides is introduced. Two different antibody panels can be immobilized easily by static coating, without using sophisticated fluid handling or bulky equipment. 5‐plexed, 3‐fluorescence color single‐cell secretion assay is demonstrated with this platform to investigate human monocytic U937 cells in response to lipopolysaccharide and phorbol myristate acetate stimulation, which identified the existence of functional subsets dictated by different cytokine profiles. The technology introduced here is simple, easy to operate, which holds great potential to become a powerful tool for profiling multiplexed single‐cell cytokine secretion at high throughput to dissect cellular heterogeneity in secretome signatures. 相似文献
923.
随着世界经济的高速发展和人口的不断增长,能源短缺和环境污染问题日益成为制约发展的瓶颈。微生物燃料电池(microbial fuel cell,MFC)能将污染物中蕴含的化学能直接转化为电能,实现同步污水处理和电能回收,是一种极具前景的可持续污水处理技术。同时,MFC在污泥处理、生物修复、环境监测、海水淡化等方面也展示了诱人的前景。基于科睿唯安Web of Science数据库和德温特专利检索分析平台(Derwent Innovation, DI),对MFC领域1990~2018年的论文和专利数据进行统计分析,得出全球MFC领域的发展趋势、国际分布、研发热点和技术格局。在此基础上,对未来MFC领域的发展做出了展望,对中国MFC产业化发展提出了思考和建议。 相似文献
924.
冠状病毒是一类可感染人类和动物的RNA病毒,可引起严重急性呼吸综合征(SARS)和中东呼吸综合征(MERS)等严重疾病。新型冠状病毒是以前从未在人体中发现的冠状病毒新毒株,其人际传播迅速,引起了各国政府的高度重视并积极寻求疫苗防控对策。基于冠状病毒疫苗领域全景专利,在综合对比分析该领域的全部专利的发展趋势、主要国家和主要机构的专利产出的同时,重点揭示了其中的人用相关疫苗的发展与分布情况以及重点分析了人用疫苗产品的研发现状,以期为我国冠状病毒疫苗领域的科研工作者和管理决策者提供参考数据。 相似文献
925.
926.
927.
Helen E. Driessen Magda S. Fontes Leonie van Stuijvenberg Maike A. Brans Marie‐Jose Goumans Marc A. Vos Toon A. van Veen 《Journal of cellular and molecular medicine》2020,24(15):8417-8429
In the diseased and remodelled heart, increased activity and expression of Ca2+/calmodulin‐dependent protein kinase II (CaMKII), an excess of fibrosis, and a decreased electrical coupling and cellular excitability leads to disturbed calcium homeostasis and tissue integrity. This subsequently leads to increased arrhythmia vulnerability and contractile dysfunction. Here, we investigated the combination of CaMKII inhibition (using genetically modified mice expressing the autocamtide‐3‐related‐peptide (AC3I)) together with eplerenone treatment (AC3I‐Epler) to prevent electrophysiological remodelling, fibrosis and subsequent functional deterioration in a mouse model of chronic pressure overload. We compared AC3I‐Epler mice with mice only subjected to mineralocorticoid receptor (MR) antagonism (WT‐Epler) and mice with only CaMKII inhibition (AC3I‐No). Our data show that a combined CaMKII inhibition together with MR antagonism mitigates contractile deterioration as was manifested by a preservation of ejection fraction, fractional shortening, global longitudinal strain, peak strain and contractile synchronicity. Furthermore, patchy fibrosis formation was reduced, potentially via inhibition of pro‐fibrotic TGF‐β/SMAD3 signalling, which related to a better global contractile performance and a slightly depressed incidence of arrhythmias. Furthermore, the level of patchy fibrosis appeared significantly correlated to eplerenone dose. The addition of eplerenone to CaMKII inhibition potentiates the effects of CaMKII inhibition on pro‐fibrotic pathways. As a result of the applied strategy, limiting patchy fibrosis adheres to a higher synchronicity of contraction and an overall better contractile performance which fits with a tempered arrhythmogenesis. 相似文献
928.
Songyu Tian Wanqi Mi Mingyue Zhang Linan Xing Chunlong Zhang 《Journal of cellular and molecular medicine》2020,24(4):2582-2592
Ovarian cancer (OvCa) causes the highest mortality among all gynaecologic cancers. A large number of mRNA‐ or miRNA‐based signatures were identified for OvCa patient prognosis. However, the comprehensive analysis of function‐level prognostic signatures is currently not considered in OvCa. In the present study, we respectively inferred subpathway activities from mRNA and miRNA levels based on high‐throughput expression profiles and reconstructed subpathways. Firstly, the activities of two tumour pathways were calculated and the difference between normal and tumour samples were analysed using multiple tumour types. Then, we calculated subpathway activities for OvCa based on the expression profiles from both mRNA and miRNA levels. Furthermore, based on these subpathway activity matrices, we performed bootstrap analysis to obtain sub‐training sets and utilized univariate method to identify robust OvCa prognostic subpathways. A comprehensive comparison of subpathway results between these two levels was performed. As a result, we observed subpathway mutual exclusion trend between the levels of mRNA and miRNA, which indicated the necessary of combining mRNA‐miRNA levels. Finally, by using ICGC data as testing sets, we utilized two strategies to verify survival predictive power of the mRNA‐miRNA combined subpathway signatures and performed comparisons with results from individual levels. It was confirmed that our framework displayed application to identify robust and efficient prognostic signatures for OvCa, and the combined signatures indeed exhibited advantages over individual ones. In the study, we took a step forward in relevant novel integrated functional signatures for OvCa prognosis. 相似文献
929.
930.
Keqing Hu Xiaoqi Wang Hongyan Hu Zhongyang Xu Jiaxing Zhang Guipeng An Guohai Su 《Journal of cellular and molecular medicine》2020,24(8):4863-4870
Intracoronary application of nicorandil can effectively reduce the myocardial no‐reflow (MNR) after percutaneous coronary intervention (PCI). We sought to investigate the mechanisms of nicorandil in preventing MNR, besides that of dilating the coronary microvasculature. A total of 60 patients undergoing PCI were enrolled and randomly divided into a nicorandil group and a control group. Before PCI, 2 mg of nicorandil or an equal volume of normal saline was injected into the coronary artery. Blood samples were collected before, 24 hours and 1 week after PCI and inflammatory cytokines were tested. In the control group, the expression of pro‐inflammatory cytokines was significantly increased, while the anti‐inflammatory cytokines were decreased 24 hours after PCI. In contrast, these changes were reversed in the nicorandil group, indicating that nicorandil regulated the inflammatory response induced by PCI. Then, proteomic analysis was performed to further elucidate the potential mechanisms. A total of 53 differentially expressed proteins (DEPs) were found 24 hours after PCI in the control group, and the changes of these relevant genes were reversed in the nicorandil group. These DEPs were significantly enriched in the inflammatory pathways. In conclusion, the intracoronary application of nicorandil before PCI can regulate the inflammatory responses induced by PCI, which might be an important mechanism of nicorandil in preventing MNR. 相似文献